Results 191 to 200 of about 10,318 (317)

How does type 2 diabetes modify the risk of Alzheimer's disease?

Alzheimer's &Dementia, Volume 22, Issue 5, May 2026.
Abstract Type 2 diabetes (T2D) and Alzheimer's disease (AD) are both increasing exponentially worldwide. T2D has also been identified as one of 14 modifiable risk factors for dementia, but the mechanism is unknown. T2D could promote dementia via vascular or AD neuropathological changes, and mechanistic hypotheses include central insulin resistance and ...
G. T. Sutherland, A. Chen, H‐T. Nguyen‐Hao, H. Mundell, E. Aladyeva, M. J. Hofer, O. Harari, S. M. Twigg   +7 more
wiley   +1 more source

Exclusion of Older Adults from Obesity Treatment Pivotal Trials of GLP-1RAs and GIP/GLP-1RAs

Journal of General Internal Medicine
Alissa S. Chen, Yixuan Liang, Kasia J. Lipska, Joseph S. Ross, Reshma Ramachandran   +4 more
openaire   +2 more sources

GLP‐1 agonists and the gut microbiome: A bidirectional relationship

British Journal of Clinical Pharmacology, Volume 92, Issue 5, Page 1309-1325, May 2026.
Abstract Glucagon‐like peptide‐1 (GLP‐1) receptor agonists have transformed the management of type 2 diabetes mellitus (T2DM) and obesity, yet their interactions with the gut microbiome remain an emerging frontier in pharmacological and metabolic research.
Srinivas Kamath, Nicole S. L. Chan, Paul Joyce   +2 more
wiley   +1 more source

Glucagon-like peptide-1 receptor agonists (GLP-1RA) for neuroprotection following aneurysmal subarachnoid haemorrhage (aSAH): a scoping review

Matt Thomas, Svetlana Mastitskaya, Samuel Parker, Ruth Cookson, Lucy Holmes, Aidan Marsh, Aravind Ramesh, Sarah Rudd, Mario Teo, Alex Mortimer   +9 more
openalex   +1 more source

The Latest topics of Standards of Care in Diabetes 2025: Focusing on GLP-1RA [PDF]

Hiroshi Bando, Michael Wood, Koji Ebe
openalex   +1 more source

Semaglutide versus caloric restriction‐induced weight loss: insights into effects on skeletal muscle mass and function

The Journal of Physiology, EarlyView.
Harsh Shah, Julio E. Ayala
wiley   +1 more source

Cardiovascular‐Kidney‐Metabolic Syndrome in People With HIV: An Emerging Frontier for Clinical Pharmacology

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1136-1140, May 2026.
As antiretroviral therapy (ART) prolongs lifespans, people with HIV (PWH) face a new syndemic: Cardiovascular‐Kidney‐Metabolic (CKM) syndrome. Yet CKM in PWH is poorly characterized. Inflammation, complex pharmacokinetic (PK) alterations, ART‐associated metabolic effects, and gut dysbiosis amplify risk. Managing CKM increases medication burden, thereby
Aaron S. Devanathan, Thomas D. Nolin
wiley   +1 more source

GLP-1RA Liraglutide Attenuates Sepsis by Modulating Gut Microbiota and Associated Metabolites. [PDF]

Nutrients
Gong B, Shi Z, Qi J, Wang F, Chen G, Su H.   +5 more
europepmc   +1 more source

GLP‐1 Receptor Agonists for Obstructive Sleep Apnea: An Otolaryngologist's Prescription?

The Laryngoscope, Volume 136, Issue 6, Page 2406-2409, June 2026.
Alina Zgardau, Ryan Chin Taw Cheong, Kenny Peter Pang, Brian W. Rotenberg   +3 more
wiley   +1 more source

Intersecting Molecular Pathways in Cardiovascular Disease and Diabetes Mellitus: Emerging Roles of Inflammation and Therapeutics

Diabetes/Metabolism Research and Reviews, Volume 42, Issue 4, May 2026.
Central illustration: Pathophysiological mechanisms linking diabetes mellitus and cardiovascular disease. Chronic hyperglycaemia, insulin resistance, and low‐grade inflammation contribute to endothelial dysfunction, myocardial fibrosis, and cardiomyocyte apoptosis.
Lilian Anagnostopoulou, Nikolaos Ktenopoulos, Anastasios Apostolos, Christos Fragoulis, Panayotis Vlachakis, Paschalis Karakasis, Marios Sagris, Nikias Milaras, Maria Drakopoulou, Andreas Synetos, Ioannis Kyriazis, Ioannis Ioannidis, Costas Tsioufis, Konstantinos Toutouzas   +13 more
wiley   +1 more source